Skip to main content

Efficacy of Eugenol to Reduce Transport Stress and Mortality of Tilapia and Yellow Perch



This project will assess the use of eugenol to enhance post-transport survival and increase loading density during long duration (>12 h) transport events. This study will be initiated with a thorough review of the literature to compile existing data on the use of sedatives during fish transport. The Upper Midwest Environmental Sciences Center (UMESC) will request and schedule a pre-submission conference with CVM to discuss needed study parameters to be included into the final study protocols prepared for the project. UMESC and the University of Wisconsin-Stevens Point (UWSP) will collaboratively prepare the protocols and then UMESC will submit the protocols to CVM through the UMESC publicly-disclosable Investigational New Animal Drug (INAD) permits for eugenol and request CVM review and protocol concurrence prior to conducting the study. Additionally, UMESC maintains a Quality Assurance Unit with a full-time Quality Assurance Officer who will assist research scientists conducting this project to comply with the CVM Good Clinical Practice regulations.

The objectives of this study:

  1. Interact with CVM to determine the study design and protocol needed to develop the
    effectiveness data to support a transport sedative claim for eugenol for selected finfish species.
    The protocol must comply with current CVM Guidance For Industry for the development of pivotal
    effectiveness data and the study data collection must with CVM Good Clinical Practices
  2. Obtain fully disclosable Investigational New Animal Drug (INAD) exemptions for the selected
    sedative to be tested from CVM.
  3. Obtain Categorical Exclusions from the requirement to complete an Environmental Assessment
    or complete an Environmental Assessment for the selected sedative prior to its use and receive concurrence from CVM Environmental Safety Team.
  4. Submit the pivotal effectiveness protocol to CVM for concurrence.
  5. Conduct pivotal effectiveness studies using the selected sedative on finfish species according to
    the CVM-concurred protocol and in compliance with CVM Good Clinical Practices regulations.
  6. Summarize the study data into a Final Study Report (FSR) and archive all study data in publicly
    accessible archives
  7. Submit the FSR to the publicly disclosable INAD file provided by CVM and request CVM review of
    the FSR and concur that the effectiveness technical section is complete for the selected sedative.
  8. Respond to CVM comments on the FSR to ultimately obtain concurrence that the effectiveness
    technical section is complete for the use of the selected sedative as a transport sedative for the
    selected species
  9. Prepare a Freedom Of Information summary of the submitted data and provide it to CVM.

Proposed Budget:

InstitutionPrincipal InvestigatorObjectivesYear 1Year 2Total
U.S. Geological Survey,
Upper Midwest
Environmental Sciences
Mark P. Gaikowski1-9$23,684$23,324$47,008
University of Wisconsin-
Stevens Point
Christopher F. Hartleb5-9$26,316$26,676$52,992
 TOTALS $50,000$50,000$100,000
Viterbo UniversityKim A. Fredricks
North American Fish Farmers Cooperative, Binford Eagle
Fisheries, LLC.
Mark Willows














Transport Sedative project outline (final).pdf

Termination Report

Award Amount


Award Number